B. Riley Securities maintains Novavax at Buy, lowers price target to $16 from $18
B. Riley Securities kept its Buy rating on Novavax but reduced its price target from $18 to $16, an 11.1% cut. The new target suggests a 63.6% upside from the Nov 5 closing price of $9.78.
How this was made

The 30-second read
Why it matters
The downgrade reflects B. Riley's revised outlook, which could trigger short‑term selling but may be mitigated by upcoming clinical data.
Market read
A fresh analyst downgrade provides a timely signal for traders to reassess NVAX positions.
What to watch
Potential upcoming data releases or partnership news could offset the downgrade.
Background
Novavax is a US‑listed biotech focused on vaccine development. Analyst price‑target adjustments are common after earnings or pipeline updates.
Ticker impact
B. Riley lowered Novavax's price target to $16 from $18, indicating a fresh downgrade.
likely downward pressure as investors price in the lower target
The new target is 11% lower than the prior one, a material change that can prompt sell‑offs.
Market effects
May weigh on other biotech stocks as analysts tighten targets.
Limited to US biotech sector.
Low
Counterpoint
Some investors may view the lower target as an opportunity if they believe the market overreacted.
Key entities
- companyNovavax
Vaccine developer (ticker NVAX).
- analystB. Riley Securities
Equity research firm issuing the rating change.




